Hilco is delighted to be instructed to seek investment in a pioneering mental health solutions platform providing a unique resource to assist with the treatment of anxiety and depression via the innovative application of digital technology. The Company has significant pipeline opportunities with large organisations and institutions and is seeking further investment to enable a rollout of its services nationwide. It uniquely placed to rapidly scale to address the acute shortage of mental health service provision.
Market Opportunity
1 in 3 people suffer from anxiety or depression. This estimate equates to 4.5 million out of the 13.5 million 8-24 year olds in the UK.
1 in 6 people suffer from anxiety disorders. This is c.80% or 1 million of the 1.25 million under 18s referred to the NHS in 2022.
The NHS is overwhelmed. As of March 2023, 61% or c. 625,000 of the referrals were on 3-18 month waiting lists (NHS data).
Highly scalable technology providing disruptive economics to traditional mental health service provision.
Company Overview
The Company has developed a proprietary, bespoke and highly scalable platform technology with an emphasis on the prevention of metal health issues by early intervention.
Services delivered via interactive inclusive e-learning programmes for pupils, teachers, and parents supported by in-house trained coaches and clinicians.
Platform utilises AI facilitating continuous integration and development, supported by an experienced and international software development team.
Accomplished management team with backgrounds in healthcare and education having delivered other platforms with large scale usage.
Services include bespoke schools and university programmes together with online coaching programmes.
Existing opportunities to substantially scale via sales through third party platforms, employee benefit providers and health insurers.
Future Exit Opportunities For Investors
IPO or trade sale. Target buyers will be UK or US healthcare companies including those in service provision, mental health, telehealth, teletherapy and insurance.
Investment Process and Further Information
On receipt of a signed non-disclosure agreement (NDA), access will be provided to a virtual data room housing additional information. To access the NDA, please click the link, sign and return via email to [email protected]
Terms and Conditions
No warranties, express or implied, are provided in relation to any information or statements made in connection to this opportunity. The information contained herein, and within the project dataroom, has not been verified by Hilco and prospective purchasers must undertake their own due diligence to satisfy themselves as to the accuracy of all such information and any statements made. Hilco’s full Terms and Conditions apply. Hilco acts as agent for the Vendor who offers for sale only such right, title and interest the Company possesses in the assets.
